In the news | 1st March 2022
Advances in Biologics Require Advances in Data Management
Throughout the past few years, there’s been a clear trend in the makeup of approvals, with biologics representing a growing percentage. But even within biologics, newer technologies like mRNA, cell, and gene therapies are gaining ground. The approvals are not one-off events, but evidence of an exciting long-term trend. Learn more from Christian Marcazzo, General Manager at IDBS, in his article published in Drug Development & Discovery.
Ensuring product, process and patient data integrity and traceability throughout the BioPharmaceutical lifecycle in the era of personalized medicine
The BioPharma industry is facing a multitude of challenging external trends, from the growth in personalized medicine to supply chain disruptions and more.
European Biomanufacturing Summit 2023
Come and join us at booth 130 in Amsterdam, to learn how an innovative tech transfer approach can revolutionize drug manufacturing in the pharmaceutical industry.
IDBS events roundup: Q1 highlights and Q2 events
IDBS associates had the opportunity to attend some events in Q1 and attendees were eager to see, hear and learn more about what’s happening in the industry.
How to improve time-to-value using GxP computer systems
Explore the benefits of GxP computer systems to improve time-to-value so that companies can speed up the development and manufacture of life-saving drugs.